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Abstract
In recent years, continuous glucose monitoring (CGM) has become increasingly available with the introduction
of devices that are specifically approved for use during pregnancy. Evidence in the form of randomized-
controlled trials and cohort studies continues to build support for the use of CGM during pregnancy to improve
measures of maternal glycemia as well as obstetric and neonatal outcomes. Based on data from the CGM in
pregnant women with type 1 diabetes (CONCEPTT) trial alongside a Swedish cohort study of real-world
outcomes of pregnant women with type 1 diabetes, the UK National Institute for Health and Clinical Excellence
(NICE) guidelines now recommend that real-time CGM be offered to all pregnant women with type 1 diabetes.
Based on these guidelines, all pregnant individuals in the United Kingdom with type 1 diabetes will receive
government-funded real-time CGM for a 12-month duration. These guidelines are a game-changer and will
continue to facilitate more widespread access to CGM use in the United Kingdom and beyond. This review
describes the role of CGM in the management of diabetes in pregnancy, discusses contemporary maternal
glucose levels and their relationship with outcomes in diabetes pregnancies, and examines the high-quality,
randomized-controlled trial and the real-world clinical data evaluating the impact of CGM use.
Keywords: Pregnancy, Diabetes, Continuous glucose monitoring, Technology, Gestational diabetes, Type 1
diabetes.
Introduction
While continuous glucose monitoring (CGM) hasbeen available for the past two decades, it is only in
recent years that we have had access to devices that are
specifically approved for use during pregnancy. Un-
doubtedly, the increasing availability, affordability, and
usability of the FreeStyle Libre (also known as intermittent
CGM or flash), which is CE marked for use in pregnancy,
have transformed the clinical management of diabetes be-
fore and during pregnancy.1 The Dexcom G6 is a game
changer in terms of real-time CGM with hypoglycemia
alerts and alarms. It is accurate enough to replace self-
monitoring of blood glucose (SMBG) for precise prandial
insulin dosing in type 1 diabetes pregnancy and is also CE
marked for use during pregnancies complicated by type 1
diabetes, type 2 diabetes, and gestational diabetes.2 The
Dexcom G6 further benefits from its interoperability,
meaning that it can be used either as a standalone real-time
CGM system for those using insulin pumps or multiple daily
injections or together with a subcutaneous insulin pump
(currently a DANA pump in Europe or Tandem T-slim
pump in North America) as part of an automated insulin
delivery system. As evidence supporting the use of CGM in
pregnancy continues to build, it is important to understand
how CGM can be leveraged to improve pregnancy outcomes
as well as to better characterize the relationship between
maternal glycemia and diabetes-related complications in
pregnancy. The aim of this review is to describe contem-
porary maternal glucose levels and their relationship with
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obstetric and neonatal outcomes in diabetes pregnancies and
to examine the high-quality, randomized-controlled trial and
the real-world clinical data evaluating the impact of CGM use.
The Changing Landscape of Diabetes in Pregnancy
The prevalence of gestational diabetes and of pregnancies
complicated by type 1 or type 2 diabetes has doubled over
recent decades, such that by the age of 30 years, almost 1 in
10 women is affected by hyperglycemia in pregnancy.3 The
increasing prevalence of pregnancies complicated by hy-
perglycemia is apparent across all types of diabetes, affecting
not only women with gestational and type 2 diabetes, but also
women with type 1 diabetes, in whom increases of 30%–40%
have been reported across Northern Europe.4 It is well es-
tablished that pregnant women with type 1 diabetes have
higher and more variable glucose levels, are more likely to
have impaired awareness to hypoglycemia, increased day to
day hypoglycemic events, and increased risk of severe hy-
poglycemia, and thus spend less time with glucose levels in
the pregnancy target range compared with pregnant women
with type 2 diabetes. For women with type 1 diabetes, who
lack biologically active pancreatic insulin secretion, it is
particularly challenging to balance the achievement of tight
pregnancy glucose targets with the risk of daily and severe
hypoglycemic events. Consequently, only a minority (*15%)
are able to achieve the recommended hemoglobin A1C (HbA1c)
target of below 48 mmol/mol (6.5%) in early pregnancy.5
Nationwide population-based data from 8685 pregnant
women with type 1 diabetes demonstrate that younger aged
women (younger than 25 years), those with more than a 5-
year duration of diabetes, higher body mass index (BMI
>25 kg/m2), and living in all except for the least deprived
regions are unlikely to achieve glycemic targets.6 Indeed, the
women most likely to achieve target HbA1c levels using
SMBG are those aged 35–44 years (who generally have
higher incomes, education and health literacy) and those with
the shortest duration of diabetes (<1 year) who likely have
residual pancreatic insulin secretion (Table 1).6
In contrast to previous data suggesting substantial clinic to
clinic variation, this large cohort demonstrated that after ad-
justing for maternal demographic and clinical characteristics,
there was no evidence of statistically significant variation in
maternal glycemia between clinics, either in early or late ges-
tation.5,6 In addition, the already high rates of preterm delivery
(before 37 weeks) and of large-for-gestational-age birthweight
Table 1. Factors Associated with Target Glycemia (Hemoglobin A1C Less
than 6.5% [48 mmol/mol]) in Early Pregnancy
Type 1 diabetes pregnancy Type 2 diabetes pregnancy
Category Odds ratio (95% CI) Category Odds ratio (95% CI)
Maternal age categorya Ethnicitye
Age 15–24 years 0.32 (0.25–0.40) Ethnicity N/A 0.99 (0.79–1.24)
Age 35–44 years 1.30 (1.11–1.52) Unknown 1.79 (1.16–2.76)





Deprivation N/A 0.70 (0.51–0.96) Deprivation N/A 0.99 (0.73–1.34)
Quintile 5 0.44 (0.35–0.55) Quintile 5 0.73 (0.57–0.93)
Quintile 4 0.48 (0.39–0.60) Quintile 4 0.84 (0.65–1.07)
Quintile 3 0.65 (0.53–0.80) Quintile 3 1.01 (0.78–1.30)
Quintile 2 0.67 (0.54–0.82) Quintile 2 1.09 (0.82–1.45)
Diabetes duration
Diabetes duration N/Ac 0.76 (0.38–1.51) Diabetes duration N/A 0.79 (0.59–1.06)
Duration <1 year 1.69 (1.11–2.57) Duration <1 year 0.86 (0.72–1.02)
Duration 5–9 years 0.54 (0.43–0.67) Duration 5–9 years 0.60 (0.52–0.68)
Duration 10–14 years 0.40 (0.32–0.50) Duration 10–14 years 0.48 (0.39–0.60)
Duration >15 years 0.43 (0.36–0.52) Duration >15 years 0.41 (0.27–0.61)
BMI (kg/m2)
BMI <18.5d 1.27 (0.71–2.29) BMI <18.5 0.86 (0.36–2.10)
BMI 25–29.9 0.75 (0.64–0.87) BMI 25–29.9 0.80 (0.66–0.97)
BMI 30–34.9 0.63 (0.51–0.77) BMI 30–34.9 0.65 (0.54–0.79)
BMI 35–39.9 0.55 (0.39–0.78) BMI 35–39.9 0.55 (0.45–0.68)
BMI >40 0.53 (0.31–0.90) BMI >40 0.52 (0.42–0.64)
Separate models were run for type 1 and type 2 diabetes. Only factors that were significant in univariate analyses were retained in the
multivariate analyses. N/A is data not available.
aReference group for maternal age category at delivery is 25–34 years. Maternal age category did not improve the model fit in type 2
diabetes and is therefore omitted.
bReference group for maternal deprivation quintile is the least deprived quintile 1.
cReference group for diabetes duration is duration 1–4 years.
dReference group for maternal BMI is the healthy BMI range of 18.5–24.9.
eReference group for maternal ethnicity is white.
BMI, body mass index.
BENEFITS OF REAL-TIME CGM IN PREGNANCY S-9
in type 1 diabetes pregnancy also seem to be increasing in recent
years and these patterns are also apparent across all diabetes
pregnancy clinics and without substantial clinic to clinic vari-
ation.6 Thus, new interventions to safely optimize antenatal
glucose levels and reduce obstetric and neonatal complications
are needed, for all pregnant women with type 1 diabetes, and
these should be implemented across all maternity clinics.
Growing Evidence Supporting CGM Use
in Pregnancy
The CONCEPTT (CGM in pregnant women with type 1
diabetes) trial provided high-quality, randomized-controlled
trial data demonstrating that the use of real-time CGM was
associated with lower HbA1c at 34 weeks, suggesting im-
proved maternal glucose levels during the late second and
early third trimesters.7 Importantly, this was accompanied by
7% higher time in range (TIR) and 5% lower time above
range (TAR) without increasing maternal hypoglycemia.
Beyond impacting surrogate markers of maternal glycemia,
using CGM led to clinically significant reductions in large for
gestational-age infants, neonatal hypoglycemia, and neonatal
intensive care unit (NICU) admissions.7 A systematic review
combining data from CONCEPTT with that of the type 1
diabetes arm of the GlucoMOMS trial also showed evidence
for a reduction in preeclampsia.7–9 This is important because
preeclampsia and its consequences of growth restriction and
preterm births are associated with substantial mother and
infant morbidity and mortality globally. Mother and infant
deaths account for 6%–7% of all deaths globally, approxi-
mately half of the global burden of deaths caused by cancer.10
A Technology Appraisal from National Health Service
(NHS) Wales reported that CGM use improves glycemic con-
trol, reduces the incidence of preeclampsia and neonatal hy-
poglycemia, and reduces admission to and duration of stay in
neonatal intensive care.8 All NHS Trusts must now adopt this
guidance, and if not, they are required to justify why it has not
been followed.11 Based on the data from CONCEPTT and the
real-world health outcomes of pregnant women with type 1
diabetes and their newborns in the Swedish study, the UK Na-
tional Institute for Health and Clinical Excellence (NICE) have
also reviewed their diabetes pregnancy guidelines (Table 2).
The NICE guidelines were updated in December 2020 to
recommend that real-time CGM be offered to all pregnant
women with type 1 diabetes.12 All pregnant women with type
1 diabetes will receive government-funded real-time CGM
for up to 12 months of duration, meaning that they can con-
tinue CGM use beyond pregnancy into the early postnatal
period. They also advise that a member of the clinical team
with expertise in CGM and flash should provide education
and support, including advising women about sources of out-
of-hours support. A list of web resources for providing out-
of-hours support is provided. This is a potential game changer
for pregnant women with type 1 diabetes and health care
professionals, in the United Kingdom and beyond.
In addition to randomized-controlled trial evidence, real-
world data on the use of real-time CGM and flash glucose
monitoring in type 1 diabetes pregnancies have confirmed the
association between CGM measures and neonatal out-
comes.13 A Swedish study of 186 women described the use of
real-time CGM (Dexcom G4) and flash glucose monitoring
(FreeStyle Libre) in type 1 diabetes pregnancies. Authors
demonstrated that a higher CGM TIR in the second and third
trimesters was associated with a decreased risk of large-for-
gestational-age and a decreased risk of their composite neo-
natal outcome (shoulder dystocia, macrosomia, neonatal
hypoglycemia, and neonatal intensive care admission). When
taken together, these randomized-controlled trial and real-
world data suggest that increasing TIR by 5% is associated
with clinically meaningful improvements in outcomes.7,13
Data regarding the use of CGM in pregnant women with type
2 diabetes are still limited. Three randomized trials performed in
the United Kingdom, Denmark, and the Netherlands included
pregnant women with both type 1 and type 2 diabetes.9,14,15
However, only small numbers of pregnant women with type 2
diabetes were included (35%, 20%, and 27% for the United
Kingdom, Denmark, and the Netherlands, respectively).9,14,15
Furthermore, the UK and Dutch studies used older generation
masked CGM sensors (known as professional or retrospective
CGM) and the Danish study used real-time CGM intermittently
rather than continuously throughout pregnancy.14,15
Only the UK study published details of the gestational
changes in CGM glucose profiles during type 2 diabetes
pregnancy showing *60% TIR during the first trimester,
rising to 65% in the second and 75% in the third trimester.16
In contrast to women with type 1 diabetes, who had only
modest reductions in TAR, women with type 2 diabetes had
substantial gestational improvements in TAR from *33%
(8 h/day) in trimester 1, 20% (4.8 h/day) in trimester 2, and
12% (3 h/day) in trimester 3.16 The reduced fetal exposure to
maternal hyperglycemia likely explains the significantly
lower rates of preterm births, large-for-gestational-age
birthweight infants, and neonatal intensive care unit admis-
sions in type 2 diabetes offspring.
While the achievement of glucose targets in pregnancy is
more common in women with type 2 diabetes compared with
those with type 1 diabetes, it would be a mistake to assume
that type 2 diabetes is a milder or less serious concern in
pregnancy. It is possible that tighter glucose targets may be
needed for optimal pregnancy outcomes in type 2 diabe-
tes.17 The recent international consensus for CGM-derived
Table 2. Summary of National Institute
for Health and Clinical Excellence Guideline
Recommendations for Use of Continuous Glucose
Monitoring in Pregnancy
Offer CGM to all pregnant women with type 1 diabetes to
help them meet their pregnancy blood glucose targets and
improve neonatal outcomes.
Offer intermittently scanned CGM (commonly referred to as
flash) to pregnant women with type 1 diabetes who are
unable to use CGM or express a clear preference for it.
Consider CGM for pregnant women who are on insulin
therapy but do not have type 1 diabetes, if:
They have problematic severe hypoglycemia (with or
without impaired awareness of hypoglycemia) or
They have unstable blood glucose levels that are causing
concern despite efforts to optimize glycemic control.
For pregnant women who are using intermittently scanned
CGM or CGM, a member of the joint diabetes and
antenatal care team with expertise in these systems should
provide education and support (including advising women
about sources of out-of-hours support).
CGM, continuous glucose monitoring; NICE, National Institute
for Health and Clinical Excellence.
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glycemic targets suggested that 90% TIR 3.5–7.8 mmol/L
(63–140 mg/dL) may be applicable with no more than 5%
TAR, and 4% time below range (TBR) may be applicable
during type 2 diabetes pregnancy (Fig. 1).18 However, given
the paucity of CGM data and no studies describing associa-
tions with pregnancy outcome, there are no evidence-based
recommendations in type 2 diabetes pregnancy.18 Given the
global increase in type 2 diabetes pregnancy and widespread
availability of more affordable user-friendly CGM devices,
data regarding the pregnancy outcomes and costs and benefits
of CGM use in this marginalized patient population are ur-
gently needed.
While CGM may also have potential for pregnancies in
individuals with gestational diabetes, evidence supporting
the use of real-time CGM remains limited. Randomized-
controlled trial evidence in gestational diabetes has been
limited to the use of retrospective or intermittent CGM.9,19
Additional trials are needed to determine if women with
gestational diabetes would benefit from real-time CGM an-
d/or flash glucose monitoring.
Using CGM and Closed-Loop Studies to Understand
How to Achieve Glucose Targets
The CONCEPTT and Swedish studies of CGM in preg-
nancy demonstrated the gap that currently exists between the
CGM TIR targets and the realities of safely achieving 70%
TIR with no more than 25% TAR in type 1 diabetes preg-
nancy.7,13 In both studies, women using multiple daily in-
jections or insulin pump therapy and with access to flash or
CGM only achieved the pregnancy glucose targets during the
third trimester. While there is an association between CGM
TIR and fetal complications both at 24 and at 34 weeks,
earlier achievement of the pregnancy TIR glucose levels is
needed for optimal neonatal outcomes.7,13,20 It is clear that
the use of CGM alone is not adequate in achieving glycemic
targets and reducing complications in pregnancy.
Closed-loop insulin delivery may help to further close the gap
between current and optimal pregnancy outcomes. Thus far data
regarding the safety and efficacy of closed-loop insulin delivery
in type 1 diabetes are limited. Early feasibility studies conducted
under strict experimental laboratory conditions suggested that
closed-loop systems could safely escalate overnight basal in-
sulin delivery as pregnancy advances and that CGM sensor
accuracy was acceptable both in early and in late gestation.21 In
addition to early feasibility studies, two small crossover
randomized-controlled trials examining overnight closed-loop
insulin delivery and day-and-night closed-loop insulin delivery
have been performed.22,23 The overnight closed-loop random-
ized crossover trial demonstrated an increase in overnight TIR
of 15% compared with sensor-augmented pump therapy.22
While the crossover trial of day-and-night closed-loop insulin
delivery did not demonstrate a significant increase in TIR in a
more diverse group of participants with higher baseline HbA1c,
it did show a significant decrease in TBR and significantly fewer
episodes of hypoglycemia.23
While early closed-loop insulin delivery studies are
promising for future clinical care, they also give us additional
insight into the importance of optimizing diet and exercise in
helping women to achieve the tight pregnancy glucose tar-
gets. Stable-label isotope studies demonstrated the relatively
small contribution of decreasing hepatic insulin sensitivity
compared with the very substantial increase in peripheral
insulin resistance, which is essential for postmeal glucose
uptake.24 Indeed, postmeal glucose disposal is substantially
delayed in late pregnancy, with weekly delays from 12 to 16
weeks onward. This is further exacerbated by delayed insulin
absorption with the time from peak plasma insulin concen-
tration increasing from *50 min in early pregnancy to
80 min in late pregnancy.24
The slower achievement of maximal postprandial plasma
insulin concentration and increased peripheral insulin resis-
tance, together impede postprandial glucose uptake, facili-
tating the prolonged duration of postprandial hyperglycemia
in late pregnancy. Thus, in addition to aggressively increas-
ing premeal boluses to stimulate peripheral muscle glucose
uptake, it is also important to administer earlier premeal
boluses as pregnancy advances. This is as essential for wo-
men using closed-loop as it is in routine clinical care. How-
ever, it is further complicated by the fact that unlike outside
FIG. 1. Continuous glucose monitoring targets in pregnancy (Adapted from Battelino et al.18) for (a) type 1 diabetes and
(b) type 2 diabetes. *Includes percentage of values <3.0 mmol/L.
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of pregnancy where insulin absorption varies greatly between
individuals, during pregnancy there is marked intraindividual
variations such that pregnant women can administer the same
bolus dose with different absorption profiles from one day to
the next.25
An interesting observation from the day and night closed-
loop feasibility studies was that even with insulin pumps and
CGM, most women struggled to achieve glucose targets in real
life but were able to do so under experimental laboratory
conditions with supervised physical activity and dietary in-
take.21 Women were provided with a choice of standardized
meals (breakfast 50 g and dinner 60 g of carbohydrate) and 15–
30 g between-meal carbohydrate snacks. They performed a
morning (09:30 h) and afternoon (15:30 h) supervised treadmill
exercise session (50 min of treadmill walking divided into
2 · 25-min sessions) in addition to short postprandial walks
after breakfast, lunch, and dinner. This had a striking impact
on maternal glucose levels with and without closed-loop in-
sulin delivery during the second trimester. Specifically, with
meticulous attention to diet and physical activity, women
(aged 32.9 years, duration of type 1 diabetes 17.6 years, BMI
27.1 kg/m2) achieved 80% TIR at *20–24 weeks of gesta-
tion, increasing to 95%–100% during the overnight period.
However, the impact of closed-loop was most apparent during
the overnight period with a 15% higher TIR and strikingly less
intraindividual variability (98 [94–100] vs. 83 [50–100])
compared with CGM and insulin pump therapy.21
Closed-loop insulin delivery was also potentially safer in
terms of hypoglycemia reduction, with fewer hypoglyce-
mia events and significantly less time below 2.5 mmol/L
(45 mg/dL). Closed-loop could not prevent exercise-related
hypoglycemia, and so, fast-acting carbohydrates were still
required especially for postmeal exercise when prandial in-
sulin is still active. These data, using older generation CGM
sensors, also suggested that CGM users should consider ad-
ditional SMBG during and after exercise.26 Although the
impact of exercise using current-generation sensors is not
clear, using SMBG to conform and monitor treatment of
hypoglycemia remains prudent.
When the glycemic profiles and physical activity energy
expenditure patterns were compared with what women did in
their everyday lives, the overall physical activity energy ex-
penditure did not substantially differ, but the 24-h mean glu-
cose concentration was strikingly lower (7.7 vs. 6.0 mmol/L)
with structured diet and exercise. Furthermore, while most
women achieved the recommended 30 min of daily exercise,
the lack of activity from 7 pm onward, usually after the largest
daily carbohydrate intake, was particularly striking and ac-
companied by almost 20% higher overnight TAR.27 The data
suggest that carefully controlled carbohydrate intake and
structured daily exercise may be needed to overcome the in-
creased peripheral insulin resistance and limit the duration of
postprandial hyperglycemia during type 1 diabetes pregnancy.
Recent insights into maternal dietary intake were obtained
from some of the CONCEPTT secondary analyses.28,29 The
application of functional data analysis to CGM data illus-
trates specific variations in temporal glucose profiles across
the 24-h day, which are not captured by TIR metrics.28 Scott
et al. demonstrated that the CONCEPTT participants using
CGM had significantly lower glucose (0.4–0.8 mmol/L
[7–14 mg/dL]) for *7 h/day, mainly during the daytime
(08.00–12.00 and 16.00–19.00) compared with women using
SMBG.28 At 24 weeks of gestation, women using insulin
pumps had similarly higher glucose levels for 12 h/day,
during the entire afternoon (13.00–18.00 h), after dinner
(20.30–00.30), and overnight (03.00–06.00 h) periods com-
pared with those on multiple daily injection therapy. This
suggests that women using multiple daily injections were
able to more effectively match their prandial insulin dose
calculations and the timing of their premeal boluses to their
dietary intake, especially for their lunch and evening meals
during the second trimester. The expected benefits of insulin
pump therapy especially for overnight glycemia (03.00–
06.00 h) were not apparent during midpregnancy. Im-
portantly, these differences in glycemia between women
using insulin pumps and multiple daily injections were not
attributed to differences in maternal dietary intake.29
The Use of CGM Is Only Part of Improving Outcomes
in Type 1 and 2 Diabetes Pregnancies
The achievement of glucose targets in pregnancy is more
common in type 2 diabetes compared with type 1 diabetes
pregnancies.5 Despite this, there are emerging data from the
United Kingdom and Scotland suggesting that the risk of se-
rious adverse pregnancy outcomes (congenital anomaly,
stillbirth, and neonatal death) is now even higher in type 2 than
in type 1 diabetes pregnancy.6,30 Nationwide population-based
data from Scotland and the United Kingdom both suggest
higher perinatal death rates in type 2 compared with type 1
diabetes pregnancy.6,30 Maternal glucose was the dominant
risk factor for perinatal death in both cohorts. It is well es-
tablished that pregnant women with type 2 diabetes are older,
have higher BMI, higher levels of social deprivation, and are
more likely to belong to the black or Asian ethnic groups than
pregnant women with type 1 diabetes.31 In addition to these
complex demographic factors, younger women with type 2
diabetes also face substantial health care inequalities, with
only a minority being offered and/or attending specialist pre-
pregnancy clinics.32,33 As a consequence, despite their in-
creased obstetric risk factors and added comorbidities of
hypertension and hyperlipidemia, women with type 2 diabetes
more frequently conceive while taking potentially harmful
medications, without adequate folic acid supplementation and
without insulin to optimize preconception glucose levels.32,33
In the UK nationwide population-based study, fewer than
one in five women of reproductive years with type 2 diabetes
were taking insulin at their first antenatal visit.6 While their
HbA1c levels are (*1% or 10 mmol/mol) lower compared
with women with type 1 diabetes, still only one-third of
women with type 2 diabetes achieve target HbA1c levels
(<48 mmol/mol or 6.5%) in early pregnancy.5 Having type 2
diabetes for 5 years or longer, an overweight (BMI
>25 kg/m2) or obese BMI category (BMI >30 kg/m2) that
includes 90% of women entering pregnancy, higher depri-
vation, and black or Asian ethnicity are all associated with
higher HbA1c levels (Table 1).6
As in type 1 diabetes, there was improvement across ges-
tation but no significant clinic to clinic variation in glycemic
attainment, either in early or late pregnancy. Thus, new in-
terventions to optimize maternal glucose levels and reduce
the modifiable risks for perinatal deaths are also urgently
needed, for all pregnant women with type 2 diabetes, and
across all maternity clinics.
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The benefits of prepregnancy care for improving pregnancy
preparation and reducing the risks of serious adverse preg-
nancy outcomes are as applicable to women with type 2 as
those with type 1 diabetes.32,33 Likewise, the reductions in
preterm births, large-for-gestational-age babies, and neonatal
intensive care unit admissions associated with optimal second
and third trimester glucose levels are also equally as applicable
for pregnant women with type 2 diabetes. However, the
stringent demands of monthly prepregnancy care clinics and
the additional time and effort required to achieve and maintain
optimal glucose levels may not be considered a high priority
for disadvantaged women.34 Qualitative research suggests that
we may also need to address the unconscious biases of women
and health care professionals in relation to fertility in women
of higher BMI and older maternal age.35
Rather than treating all pregnant women with type 1 and
type 2 diabetes similarly, specifically targeted interventions
according to the type of diabetes may be more applicable for
addressing women’s needs, improving pregnancy preparation,
and reducing adverse pregnancy outcomes. While there is an
urgent need to focus on supporting all women with diabetes to
achieve a healthy BMI before pregnancy, we may need to
strengthen the emphasis on maternal bodyweight and limiting
gestational weight gain in type 1 diabetes and on optimizing
maternal glucose levels in type 2 diabetes pregnancy.
The Importance of Continued Care
in the COVID-19 Pandemic
As a result of the pandemic, virtual care is becoming
central to the management of diabetes in pregnancy. In some
ways this may be more convenient for individuals with dia-
betes given the frequent visits required for insulin titration
throughout pregnancy due to the dynamic changes in glucose
metabolism and insulin resistance as pregnancy progresses.
The role of online CGM and insulin pump platforms such as
Clarity, CareLink, Diasend, and LibreView may be consid-
erable during the pandemic as they allow individuals with
diabetes teams to view CGM profiles remotely. There is also
a variety of online resources to support diabetes self-
management using technology during pregnancy (Table 2).
The ability to view CGM profiles on a virtual platform can
allow clinicians to offer individualized guidance to people
with diabetes without the need for an in-person visit.
Conclusions
CGM has transformed diabetes care in pregnancy with an
increasing body of evidence demonstrating that CGM can
improve maternal antenatal glucose levels and neonatal out-
comes. Over time, CGM has become increasingly user-
friendly and we now have glucose sensors that are approved
for use during pregnancy. Online CGM platforms have given
diabetes care providers access to CGM profiles in this in-
creasing world of virtual care. While the use of CGM has been
shown to improve pregnancy outcomes in type 1 diabetes,
more data are needed in pregnancies complicated by gesta-
tional and type 2 diabetes. It is also clear that diabetes tech-
nology, whether it is CGM, insulin pump therapy, or closed-
loop systems, cannot overcome all of the physiological and
pharmacological challenges of pregnancy. Health care teams
must continue to optimize the basics of diabetes treatment,
including increasing access to contraception and prepregnancy
care, timing and escalating prandial insulin dosing appropriate
to advancing gestational age, and strategically utilizing dietary
intake and daily exercise for optimal glycemia.
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